A. Mounayar

Development of a risk prediction model of potentially avoidable readmission for patients hospitalised with community-acquired pneumonia: study protocol and population

E. Sellier, B. Degano, J. Labarère, 2020, BMJ Open.

Immunosuppression in a lung transplant recipient with COVID-19? Lessons from an early case

C. Pison, M. Durand, A. Mounayar, 2020, Respiratory Medicine and Research.

Persistence at one year of neutralizing antibodies after SARS-CoV-2 infection: Influence of initial severity and steroid use

J. Payen, P. Poignard, M. Buisson, 2021, Journal of Infection.

The onset of late severe lung impairment in COVID-19 is associated with high inflammation markers at admission and metabolic syndrome markers

A. Le Gouellec, C. Schwebel, J. Brion, 2022, medRxiv.

Cluster of coronavirus disease 2019 (Covid-19) in the French Alps, 2020

J. Desenclos, D. Levy-bruhl, C. Landelle, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Incidence of Avoidable 30-Day Readmissions Following Hospitalization for Community-Acquired Pneumonia in France

E. Sellier, B. Degano, P. François, 2022, JAMA network open.